ArticleInternational journal of molecular sciences2025
Sensitivity of Various Indicators in a Mouse Sensitive Skin Model Treatment with 4-tert-Butylcyclohexanol and Pimecrolimus.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The etiopathogenesis and treatment response of sensitive skin remain poorly understood. We used 4-tert-butylcyclohexanol (4-TBLH) and 1% pimecrolimus ointment to treat sensitive skin in mice models constructed using tape stripping, propylene glycol, and capsaicin. This study aimed to further investigate the sensitivity and responsiveness of this sensitive mouse skin model. Sensitivity and responsiveness were assessed by measuring transepidermal water loss (TEWL), skin hydration, skin flakes, vascular dilatation, itching, stinging, and histological changes, including mast cell, lymphocyte, and granulocyte infiltration, tumor necrosis factor-α (TNF-α) expression, and transient receptor potential vanilloid 1 receptor (TRPV1) expression. The application of 4-TBLH and pimecrolimus revealed distinct responses in skin sensitivity indicators, including TEWL, capillary dilation, and mass cell activity, depending on the treatment timing and substance used. The prophylactic and therapeutic applications of 4-TBLH revealed distinct responses in skin sensitivity indicators, including skin flakes, TEWL, itching, stinging, epidermal thickness, mast cell activity, TNF-α, and TRPV1 expression. The prophylactic and therapeutic applications of pimecrolimus ointment revealed distinct responses in skin sensitivity indicators, including skin flakes, skin water content, itching, epidermal thickness, mast cell activity, CD45, CD11b, TNF-α, and TRPV1 expression. The mouse sensitive skin model demonstrates robust sensitivity and responsiveness to different treatment factors, and the model can be applied to the development of prophylactic and therapeutic medications for sensitive skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.